33 patents
Utility
Lanthionine Synthetase C-like 2-BASED Therapeutics
11 May 23
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
Filed: 20 Dec 22
Utility
NLRX1 Ligands
27 Apr 23
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway.
Josep Bassaganya-Riera, Andrew Leber, Nuria Tubau-Juni, Raquel Hontecillas
Filed: 20 Dec 22
Utility
Substituted imidazoles as PLXDC2 ligands
7 Mar 23
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
Filed: 29 Sep 21
Utility
Lanthionine synthetase C-like 2-based therapeutics
7 Feb 23
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
Filed: 20 Oct 20
Utility
Crystalline Forms of PIPERAZINE-1,4-DIYLBIS((6-(1H-BENZO[D]IMIDAZO-2-YL)PYRIDIN-2YL)METHANONE)
26 Jan 23
Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone), compositions containing one or more crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone), processes for preparing crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone), and methods of using crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone).
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 16 Sep 22
Utility
NLRX1 ligands
10 Jan 23
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway.
Josep Bassaganya-Riera, Andrew Leber, Nuria Tubau-Juni, Raquel Hontecillas
Filed: 20 Sep 21
Utility
Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone)
8 Nov 22
Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone), including a crystalline form of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone) having a peak within at least one 2θ value range selected from 12.4 to 12.8, 16.9 to 17.3, 20.5 to 20.9, 22.1 to 22.5, 23.2 to 23.6, and 28.2 to 28.6 degrees in an X-ray powder diffraction pattern obtained using Cu K alpha radiation, compositions containing one or more crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone), processes for preparing crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone), and methods of using crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone).
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 2 Nov 21
Utility
LANCL ligands
4 Oct 22
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 20 Oct 21
Utility
Lanthionine C-like Protein 2 Ligands, Cells Prepared Therewith, and Therapies Using Same
1 Sep 22
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 20 May 22
Utility
Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same
5 Jul 22
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 2 Aug 21
Utility
Crystalline Forms of PIPERAZINE-1,4-DIYLBIS((6-(1H-BENZO[D]IMIDAZO-2-YL)PYRIDIN-2YL)METHANONE)
5 May 22
Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone), compositions containing one or more crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone), processes for preparing crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone), and methods of using crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridine-2-yl)methanone).
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 2 Nov 21
Utility
Lancl Ligands
28 Apr 22
Provided are compounds that target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 20 Oct 21
Utility
NLRX1 Ligands
24 Mar 22
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway.
Josep Bassaganya-Riera, Andrew Leber, Nuria Tubau-Juni, Raquel Hontecillas
Filed: 20 Sep 21
Utility
Therapies with Lanthionine C-like Protein 2 Ligands and Cells Prepared Therewith
10 Mar 22
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 12 Nov 21
Utility
PLXDC2 Ligands
20 Jan 22
Provided are compounds that target plexin domain containing 2 (PLXDC2).
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
Filed: 29 Sep 21
Utility
Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith
14 Dec 21
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 16 Nov 18
Utility
PLXDC2 ligands
23 Nov 21
Provided are compounds that target plexin domain containing 2 (PLXDC2).
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
Filed: 25 Mar 21
Utility
Lanthionine C-like Protein 2 Ligands, Cells Prepared Therewith, and Therapies Using Same
18 Nov 21
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 2 Aug 21
Utility
NLRX1 Ligands
7 Oct 21
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway.
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
Filed: 17 Jun 21
Utility
PLXDC2 Ligands
7 Oct 21
Provided are compounds that target plexin domain containing 2 (PLXDC2).
Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
Filed: 25 Mar 21